Format

Send to

Choose Destination
Nat Rev Immunol. 2018 Nov;18(11):671-688. doi: 10.1038/s41577-018-0061-z.

Natural killer cells and other innate lymphoid cells in cancer.

Author information

1
Innate Pharma Research Labs, Innate Pharma, Marseille, France.
2
Aix Marseille University, CNRS, INSERM, CIML, Marseille, France.
3
CHU Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire, F-33000, Bordeaux, France.
4
Innate Pharma Research Labs, Innate Pharma, Marseille, France. vivier@ciml.univ-mrs.fr.
5
Aix Marseille University, CNRS, INSERM, CIML, Marseille, France. vivier@ciml.univ-mrs.fr.
6
Service d'Immunologie, Marseille Immunopole, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France. vivier@ciml.univ-mrs.fr.

Abstract

Immuno-oncology is an emerging field that has revolutionized cancer treatment. Most immunomodulatory strategies focus on enhancing T cell responses, but there has been a recent surge of interest in harnessing the relatively underexplored natural killer (NK) cell compartment for therapeutic interventions. NK cells show cytotoxic activity against diverse tumour cell types, and some of the clinical approaches originally developed to increase T cell cytotoxicity may also activate NK cells. Moreover, increasing numbers of studies have identified novel methods for increasing NK cell antitumour immunity and expanding NK cell populations ex vivo, thereby paving the way for a new generation of anticancer immunotherapies. The role of other innate lymphoid cells (group 1 innate lymphoid cell (ILC1), ILC2 and ILC3 subsets) in tumours is also being actively explored. This Review provides an overview of the field and summarizes current immunotherapeutic approaches for solid tumours and haematological malignancies.

PMID:
30209347
DOI:
10.1038/s41577-018-0061-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center